| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/22/2006 | EP1636225A2 Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents |
| 03/22/2006 | EP1636223A1 Benzothiazole derivatives as adenosine receptor ligands |
| 03/22/2006 | EP1636221A2 New azetidine compounds |
| 03/22/2006 | EP1636214A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 03/22/2006 | EP1636213A1 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity |
| 03/22/2006 | EP1636210A1 Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents |
| 03/22/2006 | EP1636208A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 03/22/2006 | EP1636204A1 ESTERS OF FLAVONOIDS WITH w-SUBSTITUTED C6-C22 FATTY ACIDS |
| 03/22/2006 | EP1636200A2 Inhibitors of papilloma virus |
| 03/22/2006 | EP1636198A1 Aniline derivatives |
| 03/22/2006 | EP1636197A1 Novel 3-substituted-1,4-benzodiazepines |
| 03/22/2006 | EP1636194A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 03/22/2006 | EP1636193A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 03/22/2006 | EP1636190A1 Stable crystal of 4-oxoquinoline compound |
| 03/22/2006 | EP1636183A1 Pyrrole compounds and uses thereof |
| 03/22/2006 | EP1636182A2 Prodrugs of mitotic kinesin inhibitors |
| 03/22/2006 | EP1636181A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| 03/22/2006 | EP1636176A2 The polymorphic form a of 4- 6-acetyl-3- 3-(4-acetyl-3- hydroxy-2-propylphenylthio)propoxy -2-propylphenoxy butryric acid |
| 03/22/2006 | EP1636160A2 Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders |
| 03/22/2006 | EP1636159A1 Method for the treatment or prevention of lower urinary tract symptoms |
| 03/22/2006 | EP1635909A2 Treatment of amyloid- and epileptogenesis-associated diseases |
| 03/22/2006 | EP1635875A2 In-situ gelling drug delivery system |
| 03/22/2006 | EP1635874A1 Compositions for oral administration of campothecin and its analogs |
| 03/22/2006 | EP1635873A2 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 03/22/2006 | EP1635871A2 Methods and compositions for treating rheumatoid arthritis |
| 03/22/2006 | EP1635856A2 Saposin c-dops: a novel anti-tumor agent |
| 03/22/2006 | EP1635851A2 Methods for treating cognitive impairment and improving cognition |
| 03/22/2006 | EP1635850A1 Antimicrobial silver comprising silver |
| 03/22/2006 | EP1635849A1 Medicament for internal application, in particular against cancerous diseases |
| 03/22/2006 | EP1635848A1 Methods of managing the symptoms of premenstrual syndrome |
| 03/22/2006 | EP1635847A1 Treatment of symptoms associated with bacterial vaginosis |
| 03/22/2006 | EP1635846A2 Small molecule toll-like receptor (tlr) antagonists |
| 03/22/2006 | EP1635845A1 Formoterol and ciclesonide combination |
| 03/22/2006 | EP1635844A1 Salmeterol and ciclesonide combination |
| 03/22/2006 | EP1635843A1 Therapy comprising dienogest for hormone replacement and depression |
| 03/22/2006 | EP1635842A1 Treatment of amd with combination of ingredients |
| 03/22/2006 | EP1635840A1 Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors |
| 03/22/2006 | EP1635839A2 Benzo[4,5]thieno[2,3-d]pyrimidin-4-ones and their use in therapy |
| 03/22/2006 | EP1635838A2 Prophylaxis and/or treatment of portal hypertension |
| 03/22/2006 | EP1635837A1 (3-((quinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer |
| 03/22/2006 | EP1635836A2 Prodrugs of heteroaryl compounds |
| 03/22/2006 | EP1635834A2 Novel compounds |
| 03/22/2006 | EP1635833A1 Combinations for opioid-based treatment of pain comprising 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives |
| 03/22/2006 | EP1635832A2 Combination therapy for the treatment of diabetes |
| 03/22/2006 | EP1635831A1 Combined use of ecteinascidin-743 and platinum antineoplastic compounds |
| 03/22/2006 | EP1635830A2 Granulate formulation of the rapamycin ester cci-779 |
| 03/22/2006 | EP1635826A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 03/22/2006 | EP1635825A1 Synergistic combinations including n-acylated 4-hydroxyphenylamine derivatives and caffeine |
| 03/22/2006 | EP1635823A1 Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| 03/22/2006 | EP1635822A2 Methods and compositions for treating rheumatoid arthritis |
| 03/22/2006 | EP1635821A2 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl)amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
| 03/22/2006 | EP1635820A1 Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight |
| 03/22/2006 | EP1635818A1 Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 03/22/2006 | EP1635815A1 Methods and compounds for the treatment of vascular stenosis |
| 03/22/2006 | EP1635814A1 Stable compositions of atorvastatin prepared with wet granulation |
| 03/22/2006 | EP1635813A2 Combination therapy for the treatment of dyslipidemia |
| 03/22/2006 | EP1635812A2 Beta-lactamase inhibitors and methods of use thereof |
| 03/22/2006 | EP1635811A2 Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
| 03/22/2006 | EP1635810A2 Inflammatory disease treatment |
| 03/22/2006 | EP1635808A1 Topical use of valproic acid for the prevention or treatment of skin disorders |
| 03/22/2006 | EP1635807A1 Pharmaceutical combination comprising modafinil and another drug |
| 03/22/2006 | EP1635806A2 Method for treating alcoholic hepatitis |
| 03/22/2006 | EP1635805A2 Sigma ligands for neuronal regeneration and functional recovery |
| 03/22/2006 | EP1635804A1 Use of iron for treating attention deficit hyperactivity disorder in children |
| 03/22/2006 | EP1635803A1 Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
| 03/22/2006 | EP1635802A1 Method for inhibiting the growth of antibiotic-resistant of bacteria by using pentane-1,5-diol |
| 03/22/2006 | EP1635801A2 Methods for treating and preventing cardiac arrhythmia |
| 03/22/2006 | EP1635799A2 Pharmaceutical formulations of amyloid inhibiting compounds |
| 03/22/2006 | EP1635798A2 Inhibitors of histone deacetylases for the suppression therapy of diseases |
| 03/22/2006 | EP1635796A1 Fast dissolving orally consumable films containing sucralose as a sweetener |
| 03/22/2006 | EP1635795A1 Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
| 03/22/2006 | EP1635794A2 Nitrofurantoin controlled release dosage form |
| 03/22/2006 | EP1635792A1 Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| 03/22/2006 | EP1635791A1 Pharmaceutical compositions comprising atorvastatin manufactured without granulation |
| 03/22/2006 | EP1635790A1 Pharmaceutical compositions based on diclofenac derivate |
| 03/22/2006 | EP1635789A1 Process for forming amorphous atorvastatin |
| 03/22/2006 | EP1635788A1 Pharmaceutical compositions of atorvastatin |
| 03/22/2006 | EP1635787A2 Bioerodible sustained release drug delivery systems |
| 03/22/2006 | EP1635786A2 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat |
| 03/22/2006 | EP1635783A2 Pharmaceutical compositions comprising fentanyl for intranasal delivery |
| 03/22/2006 | EP1635773A2 Combination therapy for the treatment of hypertension |
| 03/22/2006 | EP1635770A2 Antifungal nail coat and method of use |
| 03/22/2006 | EP1635689A2 Method and kit for controlling bleeding |
| 03/22/2006 | EP1635641A2 Mitotic kinesin inhibitors |
| 03/22/2006 | EP1635639A1 Use of isoindolinone derivatives as insecticides |
| 03/22/2006 | EP1601324A4 Hemostatic compositions and methods |
| 03/22/2006 | EP1587945A4 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 03/22/2006 | EP1578350A4 Sustained-release gel coated compositions |
| 03/22/2006 | EP1549650B1 Substituted c-imidazo[1,2-a]pyridin-3-yl-methylamines |
| 03/22/2006 | EP1497296B1 [1,4]DIAZOCINO[7,8,1-hi]INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS |
| 03/22/2006 | EP1480951A4 Synthesis of indole thiazole compounds as ligands for the ah receptor |
| 03/22/2006 | EP1472221B1 Substituted indoles, method for production and use thereof for the inhibition of pain |
| 03/22/2006 | EP1461436A4 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 03/22/2006 | EP1458377B1 Tegaserod pharmaceutical compositions |
| 03/22/2006 | EP1448219B1 Antiglaucomatous agent and use thereof |
| 03/22/2006 | EP1412357B1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 03/22/2006 | EP1411896B1 Surfactant compounds and uses thereof |
| 03/22/2006 | EP1406891B1 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 03/22/2006 | EP1404319B1 Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy |
| 03/22/2006 | EP1404301A4 Stable controlled release pharmaceutical compositions containing pravastatin |